Belirti Kontrolüne Dair Üstbilişler Ölçeğinin (BKDÜBÖ) ve Kısa Formunun (BKDÜBÖ-KF) Türkçe'ye Uyarlanması: Geçerlik ve Güvenirlik Çalışması

Abstract

Amaç: Üstbilişler ve psikolojik sağlık arasındaki ilişki farklı kronik fiziksel hastalıklarda araştırılmakta ve güncel çalışmalar semptom kontrolüne odaklanmaktadır. Bu çalışmanın amacı Belirti Kontrolüne Dair Üstbilişler Ölçeği (BKDÜBÖ) ve kısa formunu (BKDÜBÖ-KF) Türkçeye uyarlamak ve üstbilişlerin, İngiltere, Almanya ve Arabistan’da yaşayan kronik hastalığı olan bireylerle benzer biçimde ölçülüp ölçülemeyeceğini değerlendirmektir. Yöntem: Çalışmanın örneklemi (hem BKDÜBÖ hem BKDÜBÖ-KF için) kronik fiziksel hastalığı olan katılımcılardan (sırasıyla 81 ve 80 kişi) oluşmaktadır. Katılımcıların üstbilişleri Üstbiliş Ölçeği-30 (ÜBÖ-30) ile, genel sağlıkları Kısa Form-36 (KF-36) ile değerlendirilmiştir. Bulgular: Ölçeğin İngilizce ve orijinal hali ile tutarlı olarak hem uzun hem de kısa form iki faktörlü bir yapıya sahip ve madde dağılımları benzerdir. Güvenirlik analizleri ise her iki formun alt boyutları için iç tutarlılık katsayılarının çoğunlukla kabul edilebilir ve iyi aralıkta (.66-.83) olduğunu göstermiştir. Ölçeğin ve kısa formunun alt boyutlarının ÜBÖ-30 ve KF-36 alt boyutlarının çoğu ile orta düzeyde ilişkilere sahip olduğu görülmüştür. Sonuç: Semptom kontrolüne dair olumsuz üstbilişler alt boyutunun kültürlerarası ve tanılar üstü uyum geçerliğine sahip olduğu, semptom kontrolüne dair olumlu üstbilişler alt boyutunun ise bunu bir dereceye kadar sağladığı görülmüştür. Ölçeğin ve kısa formunun semptom kontrolüne dair olumlu üstbilişler alt boyutu için verilerin tutarsız olduğu ve daha fazla araştırılmaya ihtiyaç duyulduğu da söylenebilir. Dahası, BKDÜBÖ’nin Türkçe versiyonunun kısa formuna kıyasla daha kapsayıcı ve güvenilir olduğu görülmüştür.

Keywords

• üstbiliş
• semptom kontrolü
• psikolojik sağlık
• geçerlik
• güvenirlik

Turkish Adaptation of the Metacognitions about Symptom Control Scale and Its Revised Form: Reliability and Validity Study

Abstract

Objective: The relationship between metacognitions and mental health in different chronic physical illnesses is examined, and current studies focus on symptom control. The aim of this study is to adapt the Metacognitions about Symptom Control Scale (MaSCS) and its revised form (MaSCS-R) into Turkish and evaluate whether metacognitions can be measured in a similar way to people with chronic illnesses living in England, Germany, and Arabia. Method: The study sample (for both MaSCS and MaSCS-R) consisted of participants (81 and 80 respectively) with chronic physical illness. Participants' metacognition was assessed using the Metacognition Scale-30 (MCQ-30) and their general health was assessed using the Short Form-36 (SF-36). Results: Consistent with the English and original versions of the scale, the Turkish versions of MaSCS and MaSCS-R had a two-factor structure, and the item distributions were similar. Reliability analyses showed that internal consistency coefficients for subscales of both forms were mostly in the acceptable and good range (.66-.83). Subscales of the MaSCS and MaSCS-R were found to have moderate relationships with most of subscales of the MCQ-30 and SF-36. Conclusion: The subscale “negative metacognitions about symptom control” had cross-cultural and transdiagnostic convergent validity, while the subscale “positive metacognitions about symptom control” provided this to some extent. The results for both forms showed that positive metacognitions about symptom control are controversial and need further research. Also, the Turkish version of the MaSCS is more comprehensive and reliable than the short and revised versions.

Keywords

• metacognition
• symptom control
• mental health
• validity
• reliability

References

1. Ak M, Yazihan NT, Sütçigil L, Haciömeroglu B (2013) Metacognitive beliefs of major depression patients with suicidal behaviour. Noro Psikiyatr Ars, 50:95-99.
2. Al-Hayek AA, Robert AA, Alzaid AA, Nusair HM, Zbaidi NS, Al-Eithan MH et al. (2012) Association between diabetes self-care, medication adherence, anxiety, depression, and glycemic control in type 2 diabetes. Saudi Med J, 33:681–683.
3. Allott R, Wells A, Morrison AP, Walker R (2005) Distress in Parkinson's disease: contributions of disease factors and metacognitive style. Br J Psychiatry, 187:182-183.
4. Alves FMB, Coutinho MSSA, Sakae TM, Cosentino MB (2009) Cardiovascular risk factors in patients with non-coronarian atherosclerotic disease in hospital in the South of Brazil: case-control study. Rev Soc Bras Clin Med, 7:3-10.
5. Anderson R, Capobianco L, Fisher P, Reeves D, Heal C, Faija CL et al. (2019) Testing relationships between metacognitive beliefs, anxiety, and depression in cardiac and cancer patients: Are they transdiagnostic? J. Psychosom Res, 124:109738.
6. Ayman AAH, Asirvatham AR, Aus AA, Hussam MN, Nariman SZ, Muwafak HAE et al. (2012) Association between diabetes self-care, medication adherence, anxiety, depression, and glycemic control in type 2 diabetes. Saudi Med J, 33: 681–683.
7. Bahrami F, Yousefi N (2011) Females are more anxious than males: A metacognitive perspective. Iran J Psychiatry, 5: 83-90.
8. Boerner KE, Keogh E, Inkster AM, Nahman-Averbuch H, Oberlander TF (2024) A developmental framework for understanding the influence of sex and gender on health: Pediatric pain as an exemplar. Neurosci Biobehav Rev, 158:105546.

9. Brown RG, Fernie BA (2015) Metacognitions, anxiety, and distress related to motor fluctuations in Parkinson's disease. J. Psychosom Res, 78:143-148.
10. Bryman, A, Cramer D (2001) Quantitative Data Analysis with SPSS Release 10 for Windows: A Guide For Social Scientists. London, Routledge.
11. Capobianco L, Faija C, Husain Z, Wells A (2020) Metacognitive beliefs and their relationship with anxiety and depression in physical illnesses: A systematic review. PLoS One, 15:e0238457.
12. CDC (2023) Centers for Disease Control and Prevention Chronic Diseases in America. https://www.cdc.gov/chronicdisease (Accessed 06.08.2023)
13. Cook SA, Salmon P, Dunn G, Holcombe C, Cornford P, Fisher P (2015a). The association of metacognitive beliefs with emotional distress after diagnosis of cancer. Health Psychol, 34:207–215.
14. Cook SA, Salmon P, Dunn G, Holcombe C, Cornford P, Fisher P (2015) A prospective study of the association of metacognitive beliefs and processes with persistent emotional distress after diagnosis of cancer. Cognit Ther Res, 39:51-60.
15. Daré LO, Bruand PE, Gérard D, Marin B, Lameyre V, Boumédiène F et al. (2019) Co-morbidities of mental disorders and chronic physical diseases in developing and emerging countries: a meta-analysis. BMC Public Health, 19:304.
16. Fernie BA, Aoun A, Kollmann J, Spada MM, Nikčević AV (2019) Transcultural, transdiagnostic, and concurrent validity of a revised metacognitions about symptoms control scale. Clin Psychol Psychother, 26:471-482.
17. Fernie BA, Maher‐Edwards L, Murphy G, Nikčević AV, Spada MM (2015) The metacognitions about symptoms control scale: Development and concurrent validity. Clin Psychol Psychother, 22:443-449.
18. Fisher PL, Noble AJ (2017) Anxiety and depression in people with epilepsy: The contribution of metacognitive beliefs. Seizure, 50:153-159.
19. Fisher PL, Reilly J, Noble A (2018) Metacognitive beliefs and illness perceptions are associated with emotional distress in people with epilepsy. Epilepsy Behav, 86:9-14.
20. Flavell JH (1979) Metacognition and cognitive monitoring: A new area of cognitive–developmental inquiry. Am Psychol, 34:906–911.
21. George D, Mallery P (2003) SPSS For Windows Step by Step: A Simple Guide and Reference. 11.0 Update, 4th ed. Boston, Allyn & Bacon.
22. Ghafoor H, Ahmad RA, Nordbeck P, Ritter O, Pauli P, Schulz SM (2019) A cross‐cultural comparison of the roles of emotional intelligence, metacognition, and negative coping for health‐related quality of life in German versus Pakistani patients with chronic heart failure. Br J Health Psychol, 24:828-846.
23. Grigsby AB, Anderson RJ, Freedland KE, Clouse RE, Lustman PJ (2002) “Prevalence of anxiety in adults with diabetes: A systematic review”. J Psychosom Res, 53:1053-1060.
24. Hall RCW, Rundell JR, Hirsch TW (1996) Economic ıssues in consultation liaison psychiatry: In Textbook of Consultation Liaison Psychiatry, (Eds JR Rundell, M G Wise): 24–37. Washington DC, American Psychiatric Press.
25. Heffer-Rahn P, Fisher PL (2018) The clinical utility of metacognitive beliefs and processes in emotional distress in people with multiple sclerosis. J Psychosom Res, 104:88-94.
26. Irak M (2012) Standardization of Turkish form of metacognition questionnaire for children and adolescents: The relationships with anxiety and obsessive-compulsive symptoms. Turk Psikiyatri Derg, 23:47-54.
27. Koçyiğit H, Aydemir Ö, Fişek G, Ölmez N, Memiş A (1999) Kısa Form-36 (KF 36) Türkçe versiyonun güvenilirliği ve geçerliği: Romatizmal hastalığı olan bir grup hasta ile çalışma. İlaç Tedavi Dergisi, 12:102-106.
28. Kollmann J, Gollwitzer M, Spada MM, Fernie BA (2016) The association between metacognitions and the impact of Fibromyalgia in a German sample. J Psychosom Res, 83:1-9.
29. Maher‐Edwards L, Fernie BA, Murphy G, Nikcevic AV, Spada MM (2012) Metacognitive factors in chronic fatigue syndrome. Clin Psychol Psychother, 19:552-557.
30. Maher-Edwards L, Fernie BA, Murphy G, Wells A, Spada MM (2011) Metacognitions and negative emotions as predictors of symptom severity in chronic fatigue syndrome. J Psychosom Res, 70:311-317.
31. Mezuk B, Johnson-Lawrence V, Lee H, Rafferty JA, Abdou CM, Uzogara EE et al. (2013) Is ignorance bliss? Depression, antidepressants, and the diagnosis of prediabetes and type 2 diabetes. Health Psychol, 32:254–263.
32. Nakash O, Levav I, Aguilar‐Gaxiola S, Alonso J, Andrade LH, Angermeyer MC et al. (2014) Comorbidity of common mental disorders with cancer and their treatment gap: findings from the World Mental Health Surveys. Psychooncology, 23:40-51.
33. Purewal R, Fisher PL (2018) The contribution of illness perceptions and metacognitive beliefs to anxiety and depression in adults with diabetes. Diabetes Res Clin Pract, 136:16-22.
34. Struijs JN, Baan CA, Schellevis FG, Westert GP, van den Bos GA (2006) Comorbidity in patients with diabetes mellitus: Impact on medical health care utilization. BMC Health Serv Res, 6:84.
35. Thornicroft G, Votruba N (2015) Millennium development goals: lessons for global mental health. Epidemiol Psychiatr Sci, 24:458–460.
36. van der Heide I, Snoeijs S, Melchiorre MG, Quattrini S, Boerma W, Schellevis F et al. (2015) Innovating Care for People with Multiple Chronic Conditions in Europe. Utrecht, NIVEL.
37. Ware JE, Sherbourne CD (1992) The MOS 36-Item Short-Form Health Survey (SF-36): I. Conceptual framework and item selection. Med Care, 30:473–483.
38. Wells A, Cartwright-Hatton S (2004) A short form of the metacognitions questionnaire: Properties of the MCQ-30. Behav Res Ther, 42:385-396.
39. Wells A, Matthews G (2014) Attention and Emotion: A Clinical Perspective. East Sussex, UK, Psychology Press.
40. Wells A (2000) Emotional Disorders and Metacognition: Innovative Cognitive Therapy, New York, Wiley.
41. Wells A (2011) Metacognitive Therapy for Anxiety and Depression. New York, Guilford press.
42. Wells A (2013) Advances in Metacognitive Therapy. Int J Cogn Ther, 6:186-201.
43. WHO (2020). The top 10 causes of death. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death (Accessed 06.07.2023)
44. WHO (2022). World Mental Health Report: Transforming Mental Health for All. Geneva, World Health Organization.
45. WHO (2023) World Health Statistics 2023: Monitoring Health for The SDGS, Sustainable Development Goals. Geneva, World Health Organization.
46. Yılmaz AE, Gençöz T, Wells A (2008) Psychometric characteristics of the Penn State Worry Questionnaire and Metacognitions Questionnaire‐30 and metacognitive predictors of worry and obsessive–compulsive symptoms in a Turkish sample. Clin Psychol Psychother, 15:424-439.
47. Yılmaz AE, Sungur M, Konkan R, Şenormancı Ö (2014) Psychometric properties of the metacognition scales about rumination in clinical and non-clinical Turkish samples. Turk Psikiyatri Derg, 25:268-278.
48. Yu M, Zhang X, Lu F, Fang L (2015) Depression and risk for diabetes: A meta-analysis, Can J Diabetes, 39:266-272.